Acute allergic reaction - Revision history

Danbot: Add MedicationDose entries (diphenhydramine, cetirizine, famotidine, methylprednisolone, prednisone) with SMW annotations

2026-03-20T18:25:30Z

Add MedicationDose entries (diphenhydramine, cetirizine, famotidine, methylprednisolone, prednisone) with SMW annotations

@@ Línea 23: / Línea 23: @@
 #Consider [[corticosteroid]]: [[methylprednisolone]] 125mg IV/IM '''OR''' [[prednisone]] 60mg PO
 #*Continue steroid burst if outpatient (40mg [[prednisone]] PO x 5 days)
 ==Disposition==

Rossdonaldson1: /* Management */

2025-01-29T21:47:37Z

Management

← Revisión anterior		Revisión del 21:47 29 ene 2025
Línea 18:		Línea 18:
	#[[H1 antagonist]]: [[Diphenhydramine]] 50mg IV/IM/PO		#[[H1 antagonist]]: [[Diphenhydramine]] 50mg IV/IM/PO
	#*H1 antagonists with low sedating activity, such as fexofenadine, loratadine, cetirizine, are preferred over [[diphenhydramine]] and hydroxyzine when appropriate<ref>[Guideline] Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009 Oct. 64(10):1427-43</ref>		#*H1 antagonists with low sedating activity, such as fexofenadine, loratadine, cetirizine, are preferred over [[diphenhydramine]] and hydroxyzine when appropriate<ref>[Guideline] Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009 Oct. 64(10):1427-43</ref>
	#**[[Cetirizine]] 10mg IV (6-11 years old: 5-10 mg IV; 6 mo - 5 years: 2.5 mg IV)		#**[[Cetirizine]] 10mg IV/PO (6-11 years old: 5-10 mg IV; 6 mo - 5 years: 2.5 mg IV)
	#[[H2 antagonist]]: [[Famotidine]] 40mg '''OR''' [[ranitidine]] 150mg IV/IM/PO		#[[H2 antagonist]]: [[Famotidine]] 40mg '''OR''' [[ranitidine]] 150mg IV/IM/PO
	#*Improves urticaria but not angioedema at 2 hours<ref>Lin, RY et al. Improved Outcomes in Patients With Acute Allergic Syndromes Who Are Treated With Combined H1 and H2 Antagonists. Annals of Emergency Medicine. 36:5 NOVEMBER 2000.</ref>		#*Improves urticaria but not angioedema at 2 hours<ref>Lin, RY et al. Improved Outcomes in Patients With Acute Allergic Syndromes Who Are Treated With Combined H1 and H2 Antagonists. Annals of Emergency Medicine. 36:5 NOVEMBER 2000.</ref>

Rossdonaldson1: /* Management */

2025-01-29T20:50:30Z

Management

← Revisión anterior		Revisión del 20:50 29 ene 2025
Línea 18:		Línea 18:
	#[[H1 antagonist]]: [[Diphenhydramine]] 50mg IV/IM/PO		#[[H1 antagonist]]: [[Diphenhydramine]] 50mg IV/IM/PO
	#*H1 antagonists with low sedating activity, such as fexofenadine, loratadine, cetirizine, are preferred over [[diphenhydramine]] and hydroxyzine when appropriate<ref>[Guideline] Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009 Oct. 64(10):1427-43</ref>		#*H1 antagonists with low sedating activity, such as fexofenadine, loratadine, cetirizine, are preferred over [[diphenhydramine]] and hydroxyzine when appropriate<ref>[Guideline] Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009 Oct. 64(10):1427-43</ref>
			#**[[Cetirizine]] 10mg IV (6-11 years old: 5-10 mg IV; 6 mo - 5 years: 2.5 mg IV)
	#[[H2 antagonist]]: [[Famotidine]] 40mg '''OR''' [[ranitidine]] 150mg IV/IM/PO		#[[H2 antagonist]]: [[Famotidine]] 40mg '''OR''' [[ranitidine]] 150mg IV/IM/PO
	#*Improves urticaria but not angioedema at 2 hours<ref>Lin, RY et al. Improved Outcomes in Patients With Acute Allergic Syndromes Who Are Treated With Combined H1 and H2 Antagonists. Annals of Emergency Medicine. 36:5 NOVEMBER 2000.</ref>		#*Improves urticaria but not angioedema at 2 hours<ref>Lin, RY et al. Improved Outcomes in Patients With Acute Allergic Syndromes Who Are Treated With Combined H1 and H2 Antagonists. Annals of Emergency Medicine. 36:5 NOVEMBER 2000.</ref>

Kennybroccoli: /* Disposition */

2022-12-06T02:45:17Z

Disposition

← Revisión anterior		Revisión del 02:45 6 dic 2022
Línea 25:		Línea 25:
	==Disposition==		==Disposition==
	*Consider brief observation in the ED for improvement of symptoms		*Consider brief observation in the ED for improvement of symptoms
			*Send home with an [[anaphylaxis]] emergency plan and [[epinephrine]] autoinjector! (Epi-Pen)

	==See Also==		==See Also==

Rossdonaldson1: /* See Also */

2019-08-17T15:52:52Z

Mholtz: Text replacement - "OR" to "'''OR'''"

2017-05-31T01:48:57Z

Text replacement - "OR" to "'''OR'''"

← Revisión anterior		Revisión del 01:48 31 may 2017
Línea 18:		Línea 18:
	#[[H1 antagonist]]: [[Diphenhydramine]] 50mg IV/IM/PO		#[[H1 antagonist]]: [[Diphenhydramine]] 50mg IV/IM/PO
	#*H1 antagonists with low sedating activity, such as fexofenadine, loratadine, cetirizine, are preferred over [[diphenhydramine]] and hydroxyzine when appropriate<ref>[Guideline] Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009 Oct. 64(10):1427-43</ref>		#*H1 antagonists with low sedating activity, such as fexofenadine, loratadine, cetirizine, are preferred over [[diphenhydramine]] and hydroxyzine when appropriate<ref>[Guideline] Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009 Oct. 64(10):1427-43</ref>
	#[[H2 antagonist]]: [[Famotidine]] 40mg OR [[ranitidine]] 150mg IV/IM/PO		#[[H2 antagonist]]: [[Famotidine]] 40mg '''OR''' [[ranitidine]] 150mg IV/IM/PO
	#*Improves urticaria but not angioedema at 2 hours<ref>Lin, RY et al. Improved Outcomes in Patients With Acute Allergic Syndromes Who Are Treated With Combined H1 and H2 Antagonists. Annals of Emergency Medicine. 36:5 NOVEMBER 2000.</ref>		#*Improves urticaria but not angioedema at 2 hours<ref>Lin, RY et al. Improved Outcomes in Patients With Acute Allergic Syndromes Who Are Treated With Combined H1 and H2 Antagonists. Annals of Emergency Medicine. 36:5 NOVEMBER 2000.</ref>
	#Consider [[corticosteroid]]: [[methylprednisolone]] 125mg IV/IM OR [[prednisone]] 60mg PO		#Consider [[corticosteroid]]: [[methylprednisolone]] 125mg IV/IM '''OR''' [[prednisone]] 60mg PO
	#*Continue steroid burst if outpatient (40mg [[prednisone]] PO x 5 days)		#*Continue steroid burst if outpatient (40mg [[prednisone]] PO x 5 days)

Rossdonaldson1: Text replacement - " diphenhydramine" to " diphenhydramine"

2016-08-03T07:46:45Z

Text replacement - " diphenhydramine" to " diphenhydramine"

← Revisión anterior		Revisión del 07:46 3 ago 2016
Línea 17:		Línea 17:
	==Management==		==Management==
	#[[H1 antagonist]]: [[Diphenhydramine]] 50mg IV/IM/PO		#[[H1 antagonist]]: [[Diphenhydramine]] 50mg IV/IM/PO
	#*H1 antagonists with low sedating activity, such as fexofenadine, loratadine, cetirizine, are preferred over diphenhydramine and hydroxyzine when appropriate<ref>[Guideline] Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009 Oct. 64(10):1427-43</ref>		#*H1 antagonists with low sedating activity, such as fexofenadine, loratadine, cetirizine, are preferred over [[diphenhydramine]] and hydroxyzine when appropriate<ref>[Guideline] Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009 Oct. 64(10):1427-43</ref>
	#[[H2 antagonist]]: [[Famotidine]] 40mg OR [[ranitidine]] 150mg IV/IM/PO		#[[H2 antagonist]]: [[Famotidine]] 40mg OR [[ranitidine]] 150mg IV/IM/PO
	#*Improves urticaria but not angioedema at 2 hours<ref>Lin, RY et al. Improved Outcomes in Patients With Acute Allergic Syndromes Who Are Treated With Combined H1 and H2 Antagonists. Annals of Emergency Medicine. 36:5 NOVEMBER 2000.</ref>		#*Improves urticaria but not angioedema at 2 hours<ref>Lin, RY et al. Improved Outcomes in Patients With Acute Allergic Syndromes Who Are Treated With Combined H1 and H2 Antagonists. Annals of Emergency Medicine. 36:5 NOVEMBER 2000.</ref>

Neil.m.young: Text replacement - "==Diagnosis==" to "==Evaluation=="

2016-07-23T00:46:00Z

Text replacement - "==Diagnosis==" to "==Evaluation=="

← Revisión anterior		Revisión del 00:46 23 jul 2016
Línea 10:		Línea 10:
	{{Acute Allergic DDX}}		{{Acute Allergic DDX}}

	==~~Diagnosis~~==		==Evaluation==
	*Clinical		*Clinical
	**Rule out [[Anaphylaxis]]		**Rule out [[Anaphylaxis]]

Neil.m.young: Text replacement - " ==" to "=="

2016-07-05T18:41:23Z

Text replacement - " ==" to "=="

← Revisión anterior		Revisión del 18:41 5 jul 2016
Línea 26:		Línea 26:
	*Consider brief observation in the ED for improvement of symptoms		*Consider brief observation in the ED for improvement of symptoms

	==See Also ==		==See Also==
	*[[Anaphylaxis]]		*[[Anaphylaxis]]

Neil.m.young: Text replacement - "== " to "=="

2016-07-05T10:47:53Z

Text replacement - "== " to "=="

← Revisión anterior		Revisión del 10:47 5 jul 2016
Línea 26:		Línea 26:
	*Consider brief observation in the ED for improvement of symptoms		*Consider brief observation in the ED for improvement of symptoms

	== See Also ==		==See Also ==
	*[[Anaphylaxis]]		*[[Anaphylaxis]]

← Revisión anterior		Revisión del 15:52 17 ago 2019
Línea 28:		Línea 28:
	==See Also==		==See Also==
	*[[Anaphylaxis]]		*[[Anaphylaxis]]
			*[[Chronic urticaria]]

	==References==		==References==